BUZZ-Australia's <a href="https://laohu8.com/S/CVB.AU">CurveBeam AI</a> climbs to over 2-month high on Chinese investment approval** Shares of CurveBeam AI CVB.AX rise as much as 30.7% to A$0.098, their highest level since October 31
** The specialised medical imaging equipment developer set for its best day since late September, if gains hold
** Says Shandong WeiYing Intelligent Medical Technology gets formal Chinese regulatory approval required to make strategic investment in CurveBeam
** Says first tranche of investment from Shandong covers A$4 million ($2.70 million) with further A$6 million to be made available on achieving certain milestones
** About 6.2 million shares change hands, 10.5x their 30-day average volume
** Stock down 45.2% in 2025
($1 = 1.4824 Australian dollars)
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.